ATNM Actinium Pharmaceuticals, Inc.: institutional ownership and insider trading
53 funds reported holding $7.37M of Actinium Pharmaceuticals, Inc. in their latest 13F filings; in Q2 2026 funds net sold $704K, with 4 new positions and 12 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market.
ATNM revenue and earnings
- Quarter ended Jun 30, 2026: revenue $35.0M, net income $27.9M, EPS 0.89
- Quarter ended Mar 31, 2026: revenue n/a, net income −$5.52M, EPS -0.18
- Quarter ended Dec 31, 2025: revenue n/a, net income −$5.94M, EPS -0.20
- Quarter ended Sep 30, 2025: revenue $90.0K, net income −$5.13M, EPS -0.16
Famous investors holding ATNM
- Izzy Englander (Millennium Management): $504K, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $373K, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $254K, 0.0% of the portfolio
Largest institutional holders of ATNM
- VANGUARD GROUP INC — $1.93M
- VANGUARD CAPITAL MANAGEMENT LLC — $1.21M
- COMPASS FINANCIAL MANAGEMENT LLC — $588K
- MILLENNIUM MANAGEMENT LLC — $504K
- ACADIAN ASSET MANAGEMENT LLC — $485K
- BlackRock, Inc. (BLK) — $388K
- RENAISSANCE TECHNOLOGIES LLC — $373K
- GEODE CAPITAL MANAGEMENT, LLC — $319K
- TWO SIGMA INVESTMENTS, LP — $254K
- Nuveen Asset Management, LLC — $187K